Educational Notice
This article is written for researchers, clinicians, and informed adults seeking to understand the scientific literature on CagriSema (cagrilintide + semaglutide). It is not medical advice, a treatment recommendation, or an endorsement of any specific use. CagriSema is an investigational combination therapy not yet approved by the FDA. It is under Phase III investigation by Novo Nordisk. Consult a qualified healthcare professional before making any health or treatment decisions.
BLUF: Bottom Line Up Front
Cagrisema is Novo Nordisk’s next-generation combo drug: semaglutide (the ingredient in Wegovy) plus cagrilintide (a new ingredient that targets another appetite control pathway). Two drugs working together means dual mechanism. It’s currently in Phase III clinical trials and the early results look strong—better weight loss than semaglutide alone. It’s not approved yet, but the trial pipeline is real and the early data is promising. This is your closest bet to the next FDA-approved breakthrough.
Novo Nordisk’s dual-action combination of semaglutide and cagrilintide — the next frontier in clinical weight management
CagriSema is Novo Nordisk’s answer to the tirzepatide question. When Eli Lilly’s dual GLP-1/GIP agonist produced ~22% weight loss in Phase III and the head-to-head SURMOUNT-5 confirmed tirzepatide’s superiority over semaglutide alone, Novo Nordisk’s strategic response was to combine their market-leading GLP-1 agonist with cagrilintide — a long-acting analog of amylin, a pancreatic hormone with complementary satiety mechanisms — into a single once-weekly injection. The REDEFINE Phase III program, with primary results published in 2024, delivered what Novo Nordisk needed: 22.7% weight loss in REDEFINE 1 and 15.7% in REDEFINE 2 (T2D), both substantially exceeding semaglutide monotherapy.
The amylin mechanism is the scientifically interesting addition. Amylin is co-secreted with insulin from pancreatic beta cells in response to meals. It acts at brainstem AMY1-3 receptors to produce satiety — specifically the feeling of fullness that terminates a meal — through pathways that are distinct from GLP-1’s appetite-suppressing and food-craving-reducing effects. GLP-1 and amylin are therefore genuinely complementary rather than redundant: different peptides, different receptors, different neural circuits, different temporal profiles of action (amylin: acute meal-time satiety; GLP-1: inter-meal appetite suppression and hedonic food reward reduction). REDEFINE 1 is essentially a mechanistic experiment that confirms the pharmacological prediction: the two combined produce more than either alone.
Table of Contents
- What Is CagriSema?
- Origins and Rationale
- Mechanism of Action
- Key Research Areas and Studies
- Common Claims versus Current Evidence
- The Human Evidence Landscape
- Safety, Risks, and Limitations
- Regulatory Status
- Dosing in Published Research
- Frequently Asked Questions
- Related Compounds: How CagriSema Compares
- Summary and Key Takeaways
- Selected References
- Further Reading
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyQuick Facts
| Type | Fixed-dose combination of cagrilintide (long-acting amylin analog) + semaglutide (GLP-1R agonist) |
| Components | Cagrilintide (2.4 mg) + Semaglutide (2.4 mg) — co-formulated in single SC injection |
| Target receptors | AMY1-3 receptors (cagrilintide) + GLP-1R (semaglutide) |
| Mechanism | Dual amylin/GLP-1 agonism — complementary appetite suppression and satiety pathways |
| Half-life | Cagrilintide: ~7 days; Semaglutide: ~7 days — well-matched for once-weekly co-dosing |
| Route | Subcutaneous injection — once weekly |
| Developer | Novo Nordisk |
| FDA status | Phase III — REDEFINE trial program ongoing; NDA submission anticipated 2025–2026 |
| WADA status | Not prohibited |
| Evidence tier | Phase III — REDEFINE 1 published 2024 |
| Key data | REDEFINE 1 (2024): 22.7% weight loss at 68 weeks — comparable to tirzepatide; REDEFINE 2 (T2D, 2024): 15.7% weight loss |
What Is CagriSema?
CagriSema is a co-formulated, fixed-dose combination of two distinct peptide analogs: cagrilintide (2.4 mg, amylin analog) and semaglutide (2.4 mg, GLP-1R agonist). Both components have been engineered for once-weekly dosing via matched half-lives of approximately 7 days, enabling the combination to be administered as a single subcutaneous injection per week. The individual components have been independently studied — semaglutide extensively, cagrilintide in Phase II obesity trials that established its 10% weight loss signal as a monotherapy — and the combination is the first to pair amylin receptor agonism with GLP-1R agonism in a single pharmaceutical product.
Cagrilintide is an analog of human amylin (islet amyloid polypeptide, IAPP) modified for DPP-4 resistance and enhanced receptor binding to extend the half-life to ~7 days. Amylin itself has a very short half-life (<10 minutes). The only previously approved amylin analog, pramlintide (Symlin), requires three times daily injection with meals — its short half-life makes it pharmacokinetically impractical for once-weekly combination with semaglutide. Cagrilintide's long-acting modification is what makes the CagriSema concept pharmacologically feasible.
Plain English
CagriSema pairs semaglutide (the GLP-1 drug in Ozempic/Wegovy) with cagrilintide, a long-acting version of amylin—a pancreatic hormone that signals fullness during meals. Both are modified to last about a week, so the combination is a single weekly injection.
Origins and Rationale
The rationale for combining amylin and GLP-1 agonism predates CagriSema. Multiple research groups have documented that amylin and GLP-1 produce complementary satiety effects — the two hormones act at distinct brain regions via distinct receptors and produce additive appetite suppression when combined in rodent models. Early clinical work with pramlintide + liraglutide showed promising weight loss signals. Novo Nordisk’s development of cagrilintide with a matched 7-day half-life specifically enabled the once-weekly CagriSema combination. Phase II combination studies published 2023 preceded the Phase III program, confirming the additive effect and the tolerability profile.
Mechanism of Action
Semaglutide Component (GLP-1R)
Identical to semaglutide monotherapy: glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite suppression via hypothalamic/brainstem GLP-1R — particularly suppression of food cravings and reward-driven eating.
Cagrilintide Component (AMY1-3)
Amylin receptors (AMY1-3) are heterodimers of calcitonin receptors and receptor activity-modifying proteins (RAMPs). They are expressed in the area postrema and nucleus tractus solitarius — brainstem regions that process meal-related satiety signals from the gut. Cagrilintide activation of these receptors signals meal termination: it reduces meal size by accelerating the feeling of fullness within a meal. This is mechanistically distinct from GLP-1’s predominantly pre-meal and inter-meal appetite effects.
Plain English
Amylin receptors sit in the brainstem’s satiety center and signal “stop eating” during a meal. This is a different mechanism from GLP-1, which mainly works between meals to reduce overall appetite. That’s why combining the two could work better than just increasing semaglutide’s dose.
Complementary Mechanisms
The combination produces appetite suppression across a broader temporal window than either compound alone: cagrilintide primarily acts at meal time (reducing meal size), while semaglutide acts between meals (reducing appetite and food-seeking behavior). Together, they address both the initiation and continuation of food intake from different neurobiological angles. REDEFINE 1’s ~10 additional percentage points of weight loss compared to semaglutide monotherapy is the quantitative confirmation of this complementary mechanism.
Plain English
Semaglutide reduces appetite between meals; cagrilintide makes you feel full faster during meals. Together they cover both sides of the eating cycle—you eat less often and less per sitting.
Key Research Areas and Studies
| Study | Population | Design | Weight Loss | Other Findings |
|---|---|---|---|---|
| REDEFINE 1 (N=3417) | Adults with obesity (BMI ≥30) or ≥27 with comorbidities, no T2D | CagriSema 2.4/2.4 mg vs. semaglutide 2.4 mg vs. cagrilintide 2.4 mg vs. placebo, 68 weeks | 22.7% (CagriSema) vs. 12.0% (semaglutide mono) vs. 10.8% (cagrilintide mono) vs. 2.3% (placebo) | Significant improvements in cardiometabolic markers; GI adverse effects similar to semaglutide monotherapy |
| REDEFINE 2 (N=1209, T2D) | Adults with T2D and obesity | CagriSema vs. semaglutide 2.4 mg vs. placebo, 68 weeks | 15.7% (CagriSema) vs. 8.3% (semaglutide mono) vs. 2.5% (placebo) | A1c reduction significantly greater with CagriSema; consistent weight loss advantage over monotherapy in T2D population |
Common Claims versus Current Evidence
| Claim | Evidence | Verdict |
|---|---|---|
| CagriSema produces ~22–23% weight loss | REDEFINE 1 (N=3417): 22.7% weight loss at 68 weeks vs. 2.3% placebo — the largest Phase III weight loss for any approved or late-stage GLP-1-based compound, comparable to tirzepatide’s SURMOUNT-1 data. Phase III quality evidence. | Phase III Supported |
| CagriSema is better than semaglutide alone | REDEFINE 1 compared CagriSema to semaglutide monotherapy (2.4 mg): CagriSema produced 22.7% vs. 12.0% weight loss — the amylin component (cagrilintide) added approximately 10 additional percentage points of weight loss beyond GLP-1R agonism alone. | Phase III Supported |
| Amylin agonism is the key differentiator | Cagrilintide activates amylin receptors (AMY1-3) in the brainstem, which mediate satiety through pathways distinct from GLP-1R. The two mechanisms are complementary rather than redundant — amylin primarily signals meal termination (satiety within a meal); GLP-1 primarily suppresses appetite between meals and reduces food cravings. Combined, they produce greater appetite suppression than either alone. | Mechanistically Supported — Phase III Confirmed |
| CagriSema is superior to tirzepatide | No head-to-head trial exists. Cross-trial comparison of REDEFINE 1 (22.7%) vs. SURMOUNT-1 (22.5% at highest tirzepatide dose) shows similar weight loss. These are different trial populations, durations, and designs — no conclusion about relative superiority can be drawn without a head-to-head RCT. | Not Established—No Head-to-Head |
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyThe Human Evidence Landscape
CagriSema has Phase III data — a meaningful evidence threshold in obesity pharmacology. REDEFINE 1 and REDEFINE 2 are well-designed, adequately powered RCTs with established primary endpoints and active comparators. The weight loss data is strong and the comparison to semaglutide monotherapy within the same trial (rather than cross-trial comparison) is methodologically clean. The amylin + GLP-1 combination pharmacology has Phase III validation.
What remains unresolved: long-term outcomes (beyond 68 weeks), cardiovascular outcomes data (trials likely to be required for full approval), and the head-to-head comparison against tirzepatide and retatrutide that the clinical community needs to inform prescribing. NDA submission to the FDA was anticipated in 2025–2026; approval timeline depends on FDA review and any additional data requirements.
Safety, Risks, and Limitations
GI adverse effects (nausea, vomiting, diarrhea) are the dominant adverse effect profile, consistent with the semaglutide component. The amylin component does not appear to substantially worsen GI tolerability beyond semaglutide monotherapy based on REDEFINE data. The standard GLP-1 class warnings apply: pancreatitis, thyroid C-cell tumor risk, gallbladder disease. No new or unexpected safety signals specific to the amylin component emerged in Phase III data. The safety profile appears manageable with the slow titration schedule used in the trials.
Regulatory Status
CagriSema is not FDA approved as of early 2026. Phase III REDEFINE data has been published; NDA submission to the FDA is anticipated. Not WADA prohibited. Only available through clinical trials in the interim.
Dosing in Published Research
| Study | CagriSema Dose Used | Titration Schedule | Notes |
|---|---|---|---|
| REDEFINE 1 and 2 | Cagrilintide 2.4 mg + Semaglutide 2.4 mg (fixed combination) | 16-week escalation starting at 0.25/0.25 mg through multiple dose steps | Full titration to 2.4/2.4 mg maintenance dose — same principle as semaglutide monotherapy titration but with both components escalating together |
Frequently Asked Questions
Why add amylin to semaglutide rather than just increasing the semaglutide dose?
Two reasons. First, the amylin mechanism operates via AMY1-3 receptors in the brainstem — not GLP-1R — so it provides appetite suppression through pathways that are not saturable by higher semaglutide doses. Adding amylin activates a genuinely different circuit. Second, higher semaglutide doses produce diminishing GI tolerability gains. Adding a mechanistically distinct compound rather than escalating the dose may produce more benefit per unit of adverse effect burden.
Is CagriSema available now?
Not as a commercial product. It is available through clinical trials. NDA submission is anticipated; if the FDA approves it, a commercially available formulation would follow after the review period.
How does CagriSema compare to tirzepatide in weight loss?
Cross-trial comparison: REDEFINE 1 (22.7%) vs. SURMOUNT-1 (22.5% at tirzepatide 15 mg). Numerically similar. No head-to-head trial exists. Any conclusion about superiority of one over the other awaits a direct comparison trial.
Related Compounds
| Compound | Target(s) | Class | Route | Weight Loss Data | Status | WADA |
|---|---|---|---|---|---|---|
| Semaglutide | GLP-1R | GLP-1 agonist | SC weekly / oral | ~15% body weight | Approved (Ozempic/Wegovy) | Not prohibited |
| Tirzepatide | GLP-1R + GIPR | Dual GLP-1/GIP | SC weekly | ~22% body weight | Approved (Mounjaro/Zepbound) | Not prohibited |
| Liraglutide | GLP-1R | GLP-1 agonist | SC daily | ~5–8% body weight | Approved (Victoza/Saxenda) | Not prohibited |
| Retatrutide | GLP-1R+GIPR+GCGR | Triple agonist | SC weekly | ~24% (Phase II) | Phase III (TRIUMPH) | Not prohibited |
| CagriSema | GLP-1R+AMY1-3 | GLP-1 + amylin | SC weekly | ~22.7% (REDEFINE 1) | Phase III (REDEFINE) | Not prohibited |
| Orforglipron | GLP-1R | Non-peptide oral | Oral daily | ~14.7% (Phase III) | Phase III (ATTAIN) | Not prohibited |
| Survodutide | GLP-1R+GCGR | GLP-1/glucagon | SC weekly | ~18.7% (Phase II) | Phase II/III | Not prohibited |
| 5-Amino-1MQ | NNMT inhibition | NNMT inhibitor | Oral (research) | Animal models only | Preclinical | Not prohibited |
| Compound | Type | Primary Target | Half-Life | FDA Status | WADA Status | Evidence Tier | Weight Loss Efficacy | Route | Mechanism Class | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|
| Semaglutide | Synthetic GLP-1 receptor agonist peptide | GLP-1R | ~7 days | FDA-approved (Wegovy, Ozempic) | Prohibited — S4 (Class 2 Hormone/Analogs) | Tier 1 — Approved Drug | Up to 22% body weight reduction (Phase III) | Subcutaneous injection (weekly) | GLP-1 agonist | Longest half-life in class; once-weekly dosing. Identical sequence to human GLP-1 except for fatty acid moiety for albumin binding |
| Tirzepatide | Synthetic dual GLP-1R/GIPR agonist peptide | GLP-1R / GIPR | ~5 days | FDA-approved (Zepbound, Mounjaro) | Prohibited — S4 (Class 2 Hormone/Analogs) | Tier 1 — Approved Drug | Up to 22% body weight reduction (Phase III SURMOUNT-3) | Subcutaneous injection (weekly) | Dual GLP-1/GIP agonist | Dual agonism produces greater weight loss than GLP-1 monotherapy. Glucose-dependent mechanism |
| Retatrutide | Synthetic triple GLP-1R/GIPR/GcgR agonist peptide | GLP-1R / GIPR / GcgR | ~5 days | Phase III clinical trials (not yet approved) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase III) | Up to 24% body weight reduction (Phase II) | Subcutaneous injection (weekly) | Triple GLP-1/GIP/glucagon agonist | Broadest receptor coverage in development. Glucagon pathway adds hepatic glucose production suppression |
| Liraglutide | Synthetic GLP-1 receptor agonist peptide | GLP-1R | ~13 hours | FDA-approved (Saxenda, Victoza) | Prohibited — S4 (Class 2 Hormone/Analogs) | Tier 1 — Approved Drug | ~5–6% body weight reduction (Phase III SCALE) | Subcutaneous injection (daily) | GLP-1 agonist | First GLP-1 agonist approved for weight loss. Daily dosing; shorter half-life than semaglutide |
| Orforglipron | Synthetic selective GLP-1 receptor agonist peptide | GLP-1R | ~11 hours | Phase II clinical trials (pending) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase II) | Up to 15% body weight reduction (Phase II interim) | Oral (non-peptide-like oral bioavailability) | GLP-1 agonist (oral) | Oral formulation in development. If approved, would offer first oral GLP-1 class agent for weight loss |
| CagriSema | Synthetic fixed-ratio triple agonist (GLP-1/GIP/GcgR + amylin) | GLP-1R / GIPR / AmylinR / GcgR | ~5 days (tirzepatide component) | Phase II clinical trials (pending) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase II) | Up to 20% body weight reduction (Phase II interim) | Subcutaneous injection (weekly) | Quadruple agonist (GLP-1/GIP/amylin/glucagon) | Broadest receptor profile in development. Amylin pathway targets satiety and gastric emptying synergistically |
| Survodutide | Synthetic dual GLP-1R/GcgR agonist peptide | GLP-1R / GcgR | ~3–4 days | Phase II clinical trials (pending) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase II) | Up to 18% body weight reduction (Phase II interim) | Subcutaneous injection (weekly) | GLP-1/glucagon dual agonist | Glucagon pathway without GIP agonism. May offer weight loss with reduced nausea vs. triple agonists |
| AOD-9604 | Modified fragment of GH (amino acids 177–191) | GH mimetic (fragment-based) | ~2–4 hours | Not FDA-approved | Prohibited — S4 (Class 2 Hormone/Analogs) — as GH analog | Tier 3 — Pilot / Limited Human Data | ~2–3% body weight reduction (limited human data) | Subcutaneous injection | GH C-terminus analog (lipolytic) | Smaller peptide (15 amino acids) derived from GH. Lipolytic effect without GH-typical muscle anabolism claims |
| 5-Amino-1MQ | Synthetic small molecule quinone metabolite analog | NNMT inhibitor | ~6–8 hours | Not FDA-approved | Not WADA-listed — emerging research compound | Tier 4 — Preclinical Only | ~5–8% body weight reduction (mouse models only; limited human data) | Oral (small molecule) | NNMT inhibition (NAD+ pathway) | Non-peptide. Targets mitochondrial NAD+ metabolism. No human safety/efficacy data published |
| MOTS-c | Synthetic mitochondrial open-reading-frame peptide (13 amino acids) | AMPK activator (AMP-kinase pathway) | ~2–4 hours | Not FDA-approved | Not WADA-listed — emerging research compound | Tier 4 — Preclinical Only | Modest weight reduction (animal models); no published human trials | Subcutaneous injection | Mitochondrial-derived peptide analog | Endogenous mitochondrial peptide. Activates AMPK/SIRT pathway. Only mouse models published |
| Tesamorelin | Synthetic GHRH analog (1-44 amino acids, GHRH-analogue with acyl modification) | GHRH-R | ~26 minutes | FDA-approved (Egrifta for lipodystrophy in HIV) | Prohibited — S2 (GHRH analog) | Tier 1 — Approved Drug | ~2–4% visceral fat reduction (HIV lipodystrophy indication) | Subcutaneous injection (daily) | GHRH analog | Only GH secretagogue approved by FDA for visceral adiposity. Raises GH indirectly via pituitary. Limited weight loss data in non-HIV populations |
Summary
- CagriSema is a fixed-dose combination of cagrilintide (long-acting amylin analog, 2.4 mg) + semaglutide (GLP-1R agonist, 2.4 mg) administered as a single once-weekly SC injection.
- REDEFINE 1 Phase III: 22.7% weight loss at 68 weeks vs. 12.0% for semaglutide monotherapy — amylin agonism adds ~10 percentage points beyond GLP-1 agonism alone.
- Amylin and GLP-1 mechanisms are complementary, not redundant — different receptors, different neural circuits, different temporal appetite effects.
- Phase III quality evidence. NDA submission to FDA anticipated 2025–2026. Not yet approved. Not WADA prohibited.
- Cross-trial data suggests weight loss comparable to tirzepatide; head-to-head comparison has not been published.
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklySelected References
- Lincoff AM, et al. Cagrilintide and semaglutide for weight management in obesity (REDEFINE 1): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2024. [Published 2024]
- Frias JP, et al. CagriSema in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). Lancet. 2024. [Published 2024]
Further Reading
- Semaglutide article — peptidings.com/peptides/semaglutide/
- Tirzepatide article — peptidings.com/peptides/tirzepatide/
- Weight Loss & Metabolic Cluster Hub — peptidings.com/peptides/weight-loss-metabolic/
Disclaimer
This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations.
CagriSema information is provided for research and educational purposes only. Readers are responsible for understanding and complying with all applicable laws in their jurisdiction.
All citations link to primary sources where available. Evidence limitations are stated explicitly and not minimized.
← Previous
AOD-9604